Different regulatory framework for medical devices and drugs in the European Union: Impact on clinical research and health technology assessments
The International Journal of Health Planning and Management · 2023-09 · 38 (5) · 1420-1434
DOI: 10.1002/hpm.3671 ↗Kurz gefasst
Fachartikel in der Zeitschrift The International Journal of Health Planning and Management, online erschienen am 14.06.2023. Verfasst von Fernando Albuquerque de Almeida und 1 weiteren Autor:innen. Beteiligte Einrichtung: ESHPM - Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Understanding whether the regulatory framework in the European Union creates different standards for medical devices and drugs, assessing whether there is evidence on the impact of those standards on clinical and HTA research, and reflecting on findings in order to propose legislative changes for promoting a more efficient allocation of resources in the healthcare systems.
Methods
Reviewing and comparing the legal framework for the approval of medical devices and drugs in the EU, with a particular focus on the changes brought by Regulation (EU) 2017/745. Investigating the available information on manufacturer sponsored clinical studies and HTA‐supported recommendations for medical devices and drugs.
Results
The review of the legislation identified different standards for approval of devices and drugs on their quality, safety, and performance/efficacy dimensions and fewer manufacturer sponsored clinical studies and HTA‐supported recommendations for medical devices versus drugs.
Conclusions
Policy changes could be implemented in order to promote an integrated evidence‐based assessment system for a better allocation of resources in healthcare, namely: a consensual classification of medical devices from an HTA perspective, which could be used as a guide for generating outcomes in clinical investigation, and the adoption of conditional coverage practices including mandatory post‐approval evidence development for performing periodic technology assessments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- ESHPM - Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.
- DLA Piper, Lisbon, Portugal.
ORCID-Profile: Fernando Albuquerque de Almeida
Zitieren
APA
Albuquerque de Almeida, F., & Ricardo, M. (2023). Different regulatory framework for medical devices and drugs in the European Union: Impact on clinical research and health technology assessments. The International Journal of Health Planning and Management, 38(5), 1420-1434. https://doi.org/10.1002/hpm.3671
Vancouver
Albuquerque de Almeida F, Ricardo M. Different regulatory framework for medical devices and drugs in the European Union: Impact on clinical research and health technology assessments. The International Journal of Health Planning and Management. 2023;38(5):1420-1434. doi:10.1002/hpm.3671
BibTeX
@article{AlbuquerquedeAlmeida2023,
author = {Albuquerque de Almeida, Fernando and Ricardo, Mariana},
title = {Different regulatory framework for medical devices and drugs in the European Union: Impact on clinical research and health technology assessments},
journal = {The International Journal of Health Planning and Management},
year = {2023},
volume = {38},
number = {5},
pages = {1420--1434},
doi = {10.1002/hpm.3671}
}
EUVIMED